The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study
- PMID: 29334554
- DOI: 10.1097/SLA.0000000000002660
The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study
Abstract
Objective: Our aim was to determine the prognostic significance of the systemic-immune-inflammation index (SIII) in patients with resectable pancreatic cancer, using cancer-specific survival as the primary outcome.
Background: Pancreatic cancer is associated with a dysfunctional immune system and poor prognosis. We examined the prognostic significance of the SIII in patients with resectable pancreatic ductal adenocarcinoma (PDAC) and the effects of bilirubin on this index.
Methods: We retrospectively assessed all pancreatic resections performed between 2004 and 2015 at 4 tertiary referral centers to identify pathologically confirmed PDAC patients. Baseline clinicopathologic characteristics, preoperative laboratory values such as absolute neutrophil, lymphocyte, and platelet counts, C-reactive protein, albumin, bilirubin, and CA19-9 levels, and also follow-up information, were collected. The associations of the calculated inflammatory indices with outcome were both internally and externally validated.
Results: In all, 590 patients with resectable PDAC were included. The discovery and validation cohort included 170 and 420 patients, respectively. SIII >900 [hazard ratio (HR) 2.32, 95% confidence interval (CI) 1.55-3.48], lymph node ratio (HR 3.75, 95% CI 2.08-6.76), and CA19.9 >200 kU/L (HR 1.62, 95% CI 1.07-2.46) were identified as independent predictors of cancer-specific survival. Separate model analysis confirmed that preoperative SIII contributed significantly to prognostication. However, SIII appeared to lose its prognostic significance in patients with bilirubin levels above 200 μmol/L.
Conclusions: SIII is an independent predictor of cancer-specific survival and recurrence in patients with resectable PDAC. SIII may lose its prognostic significance in patients with high bilirubin levels. Properly designed prospective studies are needed to further confirm this hypothesis.
Similar articles
-
Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.Surgery. 2019 Jun;165(6):1151-1160. doi: 10.1016/j.surg.2018.12.015. Epub 2019 Feb 11. Surgery. 2019. PMID: 30765142
-
Changes in CRP and CA19-9 during Preoperative Oncological Therapy Predict Postoperative Survival in Pancreatic Ductal Adenocarcinoma.Oncology. 2021;99(11):686-698. doi: 10.1159/000517835. Epub 2021 Aug 19. Oncology. 2021. PMID: 34412062
-
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3. Br J Surg. 2016. PMID: 27256393
-
Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.Sci Rep. 2019 Nov 18;9(1):16971. doi: 10.1038/s41598-019-53271-6. Sci Rep. 2019. PMID: 31740696 Free PMC article.
-
Update on the management of pancreatic cancer: surgery is not enough.World J Gastroenterol. 2015 Mar 21;21(11):3157-65. doi: 10.3748/wjg.v21.i11.3157. World J Gastroenterol. 2015. PMID: 25805920 Free PMC article. Review.
Cited by
-
Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade.Front Oncol. 2021 Feb 24;11:585271. doi: 10.3389/fonc.2021.585271. eCollection 2021. Front Oncol. 2021. PMID: 33718140 Free PMC article.
-
Prognostic efficacy of the combination of the pretreatment systemic Immune-Inflammation Index and Epstein-Barr virus DNA status in locally advanced Nasopharyngeal Carcinoma Patients.J Cancer. 2021 Feb 22;12(8):2275-2284. doi: 10.7150/jca.52539. eCollection 2021. J Cancer. 2021. PMID: 33758605 Free PMC article.
-
Prognostic significance of combined Lymphocyte-monocyte Ratio and Tumor-associated Macrophages in Gastric Cancer Patients after Radical Resection.J Cancer. 2020 Jun 28;11(17):5078-5087. doi: 10.7150/jca.44440. eCollection 2020. J Cancer. 2020. PMID: 32742455 Free PMC article.
-
Systemic immune-inflammation index (SII): A More Promising Inflammation-Based Prognostic Marker for Patients with synchronic colorectal peritoneal carcinomatosis.J Cancer. 2020 Jul 9;11(18):5264-5272. doi: 10.7150/jca.46446. eCollection 2020. J Cancer. 2020. PMID: 32742472 Free PMC article.
-
The time-series behavior of systemic inflammation-immune status in predicting survival of locally advanced non-small cell lung cancer treated with chemoradiotherapy.J Natl Cancer Cent. 2021 Nov 10;2(1):33-40. doi: 10.1016/j.jncc.2021.11.003. eCollection 2022 Mar. J Natl Cancer Cent. 2021. PMID: 39035216 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials